141 related articles for article (PubMed ID: 34803670)
1. XPC Protein Improves Lung Adenocarcinoma Prognosis by Inhibiting Lung Cancer Cell Stemness.
Wang W; Ma S; Ding Z; Yang Y; Wang H; Yang K; Cai X; Li H; Gao Z; Qu M
Front Pharmacol; 2021; 12():707940. PubMed ID: 34803670
[No Abstract] [Full Text] [Related]
2. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
3. Clinical prognostic significance of xeroderma pigmentosum group C and IFN‑γ in non‑small cell lung cancer.
Wang Y; Wang W; Wang H; Qin L; Zhang M; Zhang Y; Wang Y; Hao C; Qu M; Wang G
Oncol Lett; 2024 Jun; 27(6):259. PubMed ID: 38646492
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
5. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
[TBL] [Abstract][Full Text] [Related]
6. p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression.
Wu YH; Wu TC; Liao JW; Yeh KT; Chen CY; Lee H
Cancer Res; 2010 Dec; 70(24):10422-32. PubMed ID: 21056989
[TBL] [Abstract][Full Text] [Related]
7. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
[TBL] [Abstract][Full Text] [Related]
8. Astaxanthin enhances erlotinib-induced cytotoxicity by p38 MAPK mediated xeroderma pigmentosum complementation group C (XPC) down-regulation in human lung cancer cells.
Chen JC; Wu CH; Peng YS; Zheng HY; Lin YC; Ma PF; Yen TC; Chen TY; Lin YW
Toxicol Res (Camb); 2018 Nov; 7(6):1247-1256. PubMed ID: 30555679
[TBL] [Abstract][Full Text] [Related]
9. Natural small-molecules reverse Xeroderma Pigmentosum Complementation Group C (XPC) deficient-mediated drug-resistance in renal cell carcinoma.
Chen R; Lo HH; Yang C; Law BYK; Chen X; Lam CCI; Ho C; Cheong HL; Li Q; Zhong C; Ng JPL; Peter CKF; Wong VKW
Phytomedicine; 2024 Feb; 124():155310. PubMed ID: 38215574
[TBL] [Abstract][Full Text] [Related]
10. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
11. 17-(Allylamino)-17-Demethoxygeldanamycin Enhances Etoposide-Induced Cytotoxicity via the Downregulation of Xeroderma Pigmentosum Complementation Group C Expression in Human Lung Squamous Cell Carcinoma Cells.
Chen JC; Ma PF; Lin YC; Wu CH; Peng YS; Zheng HY; Lin MC; Li YT; Lin YW
Pharmacology; 2018; 102(1-2):91-104. PubMed ID: 29953987
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients.
Bai X; Jin F; Fu Y; Yu Z; Zhao L; Ren J; Li Y; Jiao X; Zhao H; Yao W; Mi X; Wang E; Olopade OI; Zhou M; Wei M
Med Oncol; 2012 Sep; 29(3):1543-53. PubMed ID: 22038723
[TBL] [Abstract][Full Text] [Related]
13. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
Wu YH; Tsai Chang JH; Cheng YW; Wu TC; Chen CY; Lee H
Oncogene; 2007 Jul; 26(33):4761-73. PubMed ID: 17325666
[TBL] [Abstract][Full Text] [Related]
14. XPC mRNA level may predict relapse in never-smokers with non-small cell lung cancers.
Yeh KT; Wu YH; Lee MC; Wang L; Li CT; Chen CY; Lee H
Ann Surg Oncol; 2012 Mar; 19(3):734-42. PubMed ID: 21861227
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of xeroderma pigmentosum group C decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin.
Zhang Y; Cao J; Meng Y; Qu C; Shen F; Xu L
Oncol Lett; 2018 May; 15(5):6336-6344. PubMed ID: 29616110
[TBL] [Abstract][Full Text] [Related]
16. Slow accumulation of mutations in Xpc-/- mice upon induction of oxidative stress.
Melis JP; Kuiper RV; Zwart E; Robinson J; Pennings JL; van Oostrom CT; Luijten M; van Steeg H
DNA Repair (Amst); 2013 Dec; 12(12):1081-6. PubMed ID: 24084170
[TBL] [Abstract][Full Text] [Related]
17. [Expression and pathological mechanism of MMP-9 and HIF-2α in CD133(+) lung cancer stem cells].
Gao Y; Feng J; Wu L; Zhan S; Sun J
Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(32):2607-11. PubMed ID: 26711609
[TBL] [Abstract][Full Text] [Related]
18. Nucleotide Excision Repair Factor XPC Ameliorates Prognosis by Increasing the Susceptibility of Human Colorectal Cancer to Chemotherapy and Ionizing Radiation.
Hu LB; Chen Y; Meng XD; Yu P; He X; Li J
Front Oncol; 2018; 8():290. PubMed ID: 30109214
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of DERL3 Affecting the Proliferation, Invasion and Metastasis of Lung Adenocarcinoma A549 Cells].
Zhou D; Wang J; Yang K; Zhang L; Zheng Q; Bai J; Hu Y; Mu Q; Yin C; Li H
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):638-645. PubMed ID: 32838486
[TBL] [Abstract][Full Text] [Related]
20. XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression.
Cui T; Srivastava AK; Han C; Yang L; Zhao R; Zou N; Qu M; Duan W; Zhang X; Wang QE
Oncotarget; 2015 Apr; 6(12):10060-72. PubMed ID: 25871391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
